37 related articles for article (PubMed ID: 24247571)
21. D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Bandarchi B; Ma L; Marginean C; Hafezi S; Zubovits J; Rasty G
Mod Pathol; 2010 Mar; 23(3):434-8. PubMed ID: 20062007
[TBL] [Abstract][Full Text] [Related]
22. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Li N; McNiff J; Hui P; Manfioletti G; Tallini G
Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
[TBL] [Abstract][Full Text] [Related]
23. Dermatofibroma-a critical evaluation.
Zelger B; Zelger BG; Burgdorf WH
Int J Surg Pathol; 2004 Oct; 12(4):333-44. PubMed ID: 15494859
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in the diagnosis, classification and molecular pathogenesis of cutaneous mesenchymal neoplasms.
Papke DJ; Hornick JL
Histopathology; 2022 Jan; 80(1):216-232. PubMed ID: 34958499
[TBL] [Abstract][Full Text] [Related]
25. Dermatofibroma of the eyelid with monster cells.
Jakobiec FA; Tu Y; Zakka FR; Tong AKF
Surv Ophthalmol; 2017; 62(4):533-540. PubMed ID: 28012879
[TBL] [Abstract][Full Text] [Related]
26. Dermatofibromas with Aberrant Expression of CD34 Protein: A Systematic Review and a Reappraisal of Clinicopathological Features and Histogenesis.
Hussein MRA; Abdelwahed Hussein TMR
Diagnostics (Basel); 2023 Jan; 13(2):. PubMed ID: 36672995
[TBL] [Abstract][Full Text] [Related]
27. CD99 expression in dermatofibrosarcoma protuberans and dermatofibroma.
Kazlouskaya V; Malhotra S; Kabigting FD; Lal K; Elston DM
Am J Dermatopathol; 2014 May; 36(5):392-6. PubMed ID: 24247571
[TBL] [Abstract][Full Text] [Related]
28. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34.
Kim HJ; Lee JY; Kim SH; Seo YJ; Lee JH; Park JK; Kim MH; Cinn YW; Cho KH; Yoon TY
Br J Dermatol; 2007 Aug; 157(2):319-24. PubMed ID: 17596171
[TBL] [Abstract][Full Text] [Related]
29. Sclerotic fibroma-like dermatofibroma: an uncommon distinctive variant of dermatofibroma.
González-Vela MC; Val-Bernal JF; Martino M; González-López MA; García-Alberdi E; Hermana S
Histol Histopathol; 2005 Jul; 20(3):801-6. PubMed ID: 15944929
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment.
Haycox CL; Odland PB; Olbricht SM; Piepkorn M
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):438-44. PubMed ID: 9308560
[TBL] [Abstract][Full Text] [Related]
31. Current topics of immunohistochemistry as applied to skin tumors.
Hashimoto K; Fujiwara K; Mehregan A
J Dermatol; 1993 Sep; 20(9):521-32. PubMed ID: 7693783
[TBL] [Abstract][Full Text] [Related]
32. Superficial acral fibromyxoma: a CD34+ periungual tumor.
Messeguer F; Nagore E; Agustí-Mejias A; Traves V
Actas Dermosifiliogr; 2012 Jan; 103(1):67-9. PubMed ID: 22445566
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
